Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)

Lantheus said a designation and a permanent HCPCS reimbursement code effective October 1, 2026, will support patient access to PYLARIFY TruVu, its PSMA PET imaging agent. The coding milestone could improve reimbursement clarity and facilitate adoption, though the article provides no revenue or utilization estimates.

Analysis

The commercial read-through is positive but deferred: a permanent billing pathway reduces site-of-care friction and should improve ordering confidence, yet the October 2026 effective date means it is unlikely to alter near-term consensus revenue materially. The key question is whether TruVu expands the addressable imaging pool or largely migrates existing PYLARIFY scans into a new reimbursable format; the latter would be revenue-neutral unless it improves realized net price, scan volume, or retention at hospital accounts.

LNTH's more important competitive benefit is defensive. Standardized reimbursement can lower administrative burden relative to competing PSMA PET agents, strengthening formulary positioning and making it harder for newer entrants to win accounts solely through contracting. Conversely, a clearer code can also normalize the category and reduce barriers for competitors, so the differentiator shifts toward radiopharmacy distribution reliability, physician preference, and payer coverage rather than technology alone.

Near term, this is a sentiment catalyst rather than an earnings catalyst; avoid extrapolating a regulatory milestone into a 2026 revenue step-up before management quantifies utilization, reimbursement economics, and incremental production capacity. Over the next 6-18 months, the thesis is falsified if LNTH reports flat PSMA scan volumes, worsening PYLARIFY net pricing, or formulary share losses despite improved coding. A material reimbursement-policy change or payer restrictions on repeat imaging would also undermine the access thesis.

Key Decisions for Investors

• Maintain LNTH as a watch-to-accumulate rather than chase on this release; add only if subsequent earnings quantify TruVu as incremental volume or pricing upside, not product migration. The relevant catalyst window is the next 2-4 quarterly updates, well ahead of the October 2026 code effective date.
• For a position initiated on weakness, frame LNTH as a 6-18 month long with risk controlled by a stop/reassessment on two consecutive quarters of declining PYLARIFY volume or explicit guidance for PSMA net-price pressure. Upside requires evidence that streamlined reimbursement lifts hospital utilization and share.
• Monitor Telix Pharmaceuticals (TLX) and other PSMA-imaging entrants for contracting or formulary announcements. If competitors secure broad US payer access before the code becomes effective, LNTH's coding advantage is likely category-enabling rather than company-specific, reducing the case for multiple expansion.
• Do not buy near-dated LNTH calls solely on the designation: the main operational milestone is more than a year away, while the missing variables—coverage terms, provider adoption, and realized reimbursement—make a near-term earnings surprise difficult to underwrite.